Hematologic Oncology | Specialty

Post Remission Decisions in AML

December 1st 2016

AML: Induction Therapy and Minimal Residual Disease

December 1st 2016

Genetic Complexities in AML

December 1st 2016

Third-Generation TKI Most Promising Option for Ph+ ALL

November 30th 2016

Tyrosine-kinase inhibitors have considerably improved survival outcomes for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

June's Quest to Develop Gene Therapies Is a Neverending Research Story

November 30th 2016

As with software upgrades, Carl H. June, MD, sees his work in cancer research as a job with ever-evolving updates.

FDA Grants Ponatinib Full Approval for Rare Leukemias

November 29th 2016

The FDA has granted a full approval and label update to ponatinib for patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other tyrosine kinase inhibitor therapy is indicated, as well as for patients with T315I-positive CML or T315I-positive Ph+ ALL.

Dr. Eytan Stein on Novel Combinations in AML

November 29th 2016

Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the potential combinations that could be explored with novel agents in the treatment of patients with acute myeloid leukemia.

Clinical Hold Again Placed on Phase II Trial of JCAR015 in ALL

November 24th 2016

For a second time, a clinical hold has been placed on the phase II ROCKET study exploring the CD19-targeted CAR T-cell therapy JCAR015 for adult patients with relapsed or refractory B cell acute lymphoblastic leukemia.

Novel Agent Aims to Improve HCT Outcomes in High-Risk AML

November 23rd 2016

A clinical trial that utilizes a novel radiolabeled antibody–drug conjugate to pretreat older patients with relapsed or refractory acute myeloid leukemia as part of a stem cell transplantation regimen is aimed at creating improved outcomes for a high-risk population with limited therapeutic alternatives.

EC Approves Nivolumab for Hodgkin Lymphoma

November 23rd 2016

The European Commission has approved nivolumab for the treatment of patients with relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.

Expert Emphasizes Need to Enhance Treatment Strategies for Indolent Lymphomas

November 22nd 2016

Investigators are exploring therapy options for patients with indolent lymphomas—including follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma—as rituximab regimens are proving to not be a long-term option for many patients.

FDA Grants Midostaurin Priority Review for AML

November 14th 2016

The FDA granted a priority review to a new drug application for midostaurin (PKC412) for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia or advanced systemic mastocytosis.

Immunotherapy Combo Regimens on Horizon in Lymphoma

November 12th 2016

Nivolumab (Opdivo) may be the only checkpoint inhibitor that is approved by the FDA as a treatment of patients with Hodgkin lymphoma, but other immunotherapies—alone and in combination with other novel agents—are emerging in other indications.

FDA Grants Brentuximab Vedotin Breakthrough Designation in CTCL

November 12th 2016

Brentuximab vedotin (Adcetris) has received an FDA breakthrough therapy designation for the treatment of patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large cell lymphoma following at least 1 prior systemic therapy.

FDA Approves Mylotarg for AML Treatment

November 9th 2016

The FDA has approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML).

Dr. Witzig on Emerging Agents in Diffuse Large B-Cell Lymphoma

November 8th 2016

Thomas E. Witzig, MD, hematologist-oncologist, Mayo Clinic, discusses some of the emerging agents being utilized in the treatment of patients with diffuse large B-cell lymphoma.

Dr. Duvic on Importance of Classifying T-Cell Lymphomas

November 4th 2016

Madeleine Duvic, MD, professor of Medicine and Dermatology, Blanche Bender Professorship in Cancer Research, director of the Research Fellowship Program, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of classifying T-cell lymphomas and new targets in development. Duvic shared this insight during the 2016 OncLive State of the Science Summit on Hematologic Malignancies.

Dr. Garcia-Manero on Curing Patients With MDS and AML

November 2nd 2016

Guillermo Garcia-Manero, MD, professor of Medicine, chief, Section of Myelodysplastic Syndromes, in the Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential of curing patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Garcia-Manero explained this reasoning in an interview during the 2016 OncLive State of the Science Summit on Treatment of Hematologic Malignancies.

Practitioner Predicts Promising Future for MDS, AML Care

November 2nd 2016

When envisioning the future treatment paradigms for myelodysplastic syndromes and acute myeloid leukemia, researchers predict that hypomethylating agents, immunotherapies, and multikinase and BCL-2 inhibitors are just a few examples of what the field can expect in the coming years.

Dr. Jabbour on Emerging Subsets in ALL

October 29th 2016

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent treatment advances and emerging subsets in acute lymphoblastic leukemia (ALL).